Molecular Endocrinology, doi:10.1210/me.2004-0305
Molecular Endocrinology 19 (1): 175-183
Copyright © 2005 by The Endocrine Society
Farnesylthiosalicylic Acid Inhibits Mammalian Target of Rapamycin (mTOR) Activity Both in Cells and in Vitro by Promoting Dissociation of the mTOR-Raptor Complex
Lloyd P. McMahon,
Wei Yue,
Richard J. Santen and
John C. Lawrence, Jr
Departments of Pharmacology (L.P.M., J.C.L.) and Internal Medicine (W.Y., R.J.S.), University of Virginia Health System, Charlottesville, Virginia 22908
Address all correspondence and requests for reprints to: Dr. John C. Lawrence, Jr., Department of Pharmacology, P.O. Box 800735, University of Virginia Health System, 1300 Jefferson Park Avenue, Charlottesville, Virginia 22908. E-mail: jcl3p{at}virginia.edu.
The mammalian target of rapamycin (mTOR) functions with raptor and mLST8 in a signaling complex that controls rates of cell growth and proliferation. Recent results indicate that an inhibitor of the Ras signaling pathway, farnesylthiosalicylic acid (FTS), decreased phosphorylation of the mTOR effectors, PHAS-I and S6K1, in breast cancer cells. Here we show that incubating 293T cells with FTS produced a stable change in mTOR activity that could be measured in immune complex kinase assays using purified PHAS-I as substrate. Similarly, FTS decreased the PHAS-I kinase activity of mTOR when added to cell extracts or to immune complexes containing mTOR. Incubating either cells or extracts with FTS also decreased the amount of raptor that coimmunoprecipitated with mTOR, although having relatively little effect on the amount of mLST8 that coimmunoprecipitated. The concentration effect curves of FTS for inhibition of mTOR activity and for dissociation of the raptor-mTOR complex were almost identical. Caffeine, wortmannin, LY294002, and rapamycin-FKBP12 also markedly inhibited mTOR activity in vitro, but unlike FTS, none of the other mTOR inhibitors appreciably changed the amount of raptor associated with mTOR. Thus, our findings indicate that FTS represents a new type of mTOR inhibitor, which acts by dissociating the functional mTOR-raptor signaling complex.
This article has been cited by other articles:

|
 |

|
 |
 
X. Wang, P. Yue, Y. A. Kim, H. Fu, F. R. Khuri, and S.-Y. Sun
Enhancing Mammalian Target of Rapamycin (mTOR)-Targeted Cancer Therapy by Preventing mTOR/Raptor Inhibition-Initiated, mTOR/Rictor-Independent Akt Activation
Cancer Res.,
September 15, 2008;
68(18):
7409 - 7418.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Wang, T. E. Harris, R. A. Roth, and J. C. Lawrence Jr
PRAS40 Regulates mTORC1 Kinase Activity by Functioning as a Direct Inhibitor of Substrate Binding
J. Biol. Chem.,
July 6, 2007;
282(27):
20036 - 20044.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Reinke, J. C.-Y. Chen, S. Aronova, and T. Powers
Caffeine Targets TOR Complex I and Provides Evidence for a Regulatory Link between the FRB and Kinase Domains of Tor1p
J. Biol. Chem.,
October 20, 2006;
281(42):
31616 - 31626.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Matsushima, N. Harada, N. J. G. Webster, Y. M. Tsutsumi, and Y. Nakaya
Effect of TRB3 on Insulin and Nutrient-stimulated Hepatic p70 S6 Kinase Activity
J. Biol. Chem.,
October 6, 2006;
281(40):
29719 - 29729.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Wang, C. J. Rhodes, and J. C. Lawrence Jr.
Activation of Mammalian Target of Rapamycin (mTOR) by Insulin Is Associated with Stimulation of 4EBP1 Binding to Dimeric mTOR Complex 1
J. Biol. Chem.,
August 25, 2006;
281(34):
24293 - 24303.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R J Santen, R X Song, Z Zhang, R Kumar, M-H Jeng, A Masamura, J Lawrence Jr, L Berstein, and W Yue
Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity
Endocr. Relat. Cancer,
July 1, 2005;
12(Supplement_1):
S61 - S73.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 by The Endocrine Society